Stay updated with breaking news from Neuronetics Daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neuronetics, Inc. (NASDAQ:STIM – Get Rating) – Equities researchers at William Blair cut their Q2 2023 earnings per share (EPS) estimates for Neuronetics in a research note issued to investors on Tuesday, May 9th. William Blair analyst M. Kaczor now forecasts that the company will earn ($0.36) per share for the quarter, down from their […]
Neuronetics (NASDAQ:STIM – Get Rating) and Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations. Volatility and Risk Neuronetics has a beta […]
Neuronetics, Inc. (NASDAQ:STIM – Get Rating) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 394,500 shares, an increase of 53.7% from the March 15th total of 256,700 shares. Currently, 1.5% of the shares of the stock are sold short. Based on an […]
Neuronetics, Inc. (NASDAQ:STIM – Get Rating) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 394,500 shares, an increase of 53.7% from the March 15th total of 256,700 shares. Approximately 1.5% of the company’s stock are sold short. Based on an average daily […]
Neuronetics, Inc. (NASDAQ:STIM – Get Rating) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 256,700 shares, a growth of 23.6% from the February 28th total of 207,700 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an […]